<DOC>
	<DOCNO>NCT00550420</DOCNO>
	<brief_summary>This Phase III , multicenter , open-label extension , single-group study male female outpatient mild-to-moderate Alzheimer 's disease ( AD ) complete AVA105640 . All subject receive rosiglitazone extended-release ( RSG XR ) 4mg daily first 4 week study follow 8mg RSG XR . Subject participation last one 5 condition applies . After 52-week open-label treatment phase , subject attend final Follow-Up Visit 6 week end treatment . The primary objective study evaluate long-term safety tolerability RSG XR subject mild-to-moderate AD complete AVA105640 . The secondary objective study explore long-term efficacy RSG XR term cognitive function overall clinical response function apolipoprotein E ( APOE ) e4 allele status</brief_summary>
	<brief_title>Study Of Rosiglitazone XR In Subjects With Mild-to-Moderate Alzheimers</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Inclusion criterion : Male female subject successfully complete Visit 8 AVA105640 without safety/tolerability issue , opinion subject /carer investigator , would beneficial receive RSG XR Female subject able bear child must agree use adequate method contraception duration study detail highly effective method avoid pregnancy ) . Female subject premenopausal postmenopausal &lt; 1 year must undertake pregnancy test ( urine test ) £7 day Visit 1 , must negative Subject willing participate extension study provide full write informed consent prior performance protocolspecified procedure ; unable provide inform consent due cognitive status , full write informed consent behalf subject provide legally acceptable representative ( accordance local law , regulation ethic committee policy ) Subject live ( substantial period contact ) regular caregiver willing attend visit , oversee subject 's compliance protocolspecified procedure study medication , report subject 's status Subject ability comply procedure cognitive test Caregiver provide full write informed consent behalf prior performance protocolspecified procedure Subjects consider enrollment must QTc ( either QTc B ( Bazett 's correction ) QTc F ( Fridericia 's correction ) ) &lt; 450msec Visit 1 , exception subject bundle branch block ( either QTc B QTc F must &lt; 480msec ) In France , subject eligible inclusion study either affiliate beneficiary social security category Postmenopause [ Becker , 2001 ] : Menopause age associate complete cessation menstrual cycle , menses , implies loss reproductive potential ovarian failure . This typically occur around age 50 , although may occur early . A practical definition accepts menopause one year without menses appropriate clinical profile , e.g. , age appropriate , &gt; 45 year , absence hormone replacement therapy . In questionable case , blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 140 pmol/L ) confirmatory ( level suggest guideline may need adjust specific laboratories/assays Females , hormone replacement therapy ( HRT ) , whose menopausal status doubt , require use highly effective method avoid pregnancy , outline protocol , wish continue HRT study . Otherwise , must discontinue HRT allow confirmation post‑menopausal status prior study enrollment . For form HRT , least 24 week elapse cessation therapy blood draw detail precede paragraph ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use highly effective method avoid pregnancy A noncohabiting caregiver must spend sufficient time subject , opinion Investigator , caregiver reliably assess cognitive function , activity behaviour , report subject 's compliance health . As caregiver time spend potential subject anticipate highly variable across country culture , GSK consider variety different measure stipulation may meet , GSK consult adequacy caregiver situation doubt . However , guidance , ability caregiver meet his/her expect responsibility study would normally possible caregiver spend less 10 hour per week subject , divide multiple day For purpose criterion , QTc B define ( QT interval [ msec ] ) / ( square root RR interval [ second ] ) ; QTc F define ( QT interval [ msec ] ) / ( cube root RR interval [ second ] ) Exclusion criterion : Subject serious adverse experience clinically significant laboratory abnormality AVA105640 , opinion investigator could attributable study medication , ongoing Visit 1 The subject felt investigator unsuitable ( basis health , compliance , caregiver availability , reason ) inclusion study The subject experience significant cardiovascular event AVA105640 ( e.g . intervention , percutaneous coronary intervention , vascular surgery , acute coronary syndrome [ non Qwave myocardial infarction , Qwave myocardial infarction , unstable angina ] significant arrhythmia ) , unless thorough cardiovascular evaluation perform confirms subject congestive heart failure , clinically stable Clinical/investigational evidence congestive heart failure define New York Heart Association ( NYHA ) criterion ( Class I IV cardiac status ) time Visit 1 Clinically significant peripheral oedema time Visit 1 Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase value &gt; 2.5 time upper limit normal ( ULN ) , total bilirubin value &gt; 1.5 time ULN , history severe hepatobiliary disease ( e.g . hepatitis B C , cirrhosis , ChildPugh Class B/C ) Subject immediate family member employee participate Investigator , participate site staff , GSK In France , subject neither affiliated beneficiary social security category In France , subject participate study use investigational drug previous 30 day ( except participation AVA105640 )</criteria>
	<gender>All</gender>
	<minimum_age>51 Years</minimum_age>
	<maximum_age>91 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>open-label extension</keyword>
	<keyword>tolerability</keyword>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Rosiglitazone extended-release ( XR )</keyword>
	<keyword>safety</keyword>
	<keyword>cognition</keyword>
	<keyword>BRL-049653</keyword>
</DOC>